Hepatitis C Virus RNA Levels During Interferon-Free Combination Direct-Acting Antiviral Treatment in Registrational Trials TO THE EDITOR-We read with interest the unexpected findings by Sidharthan et al that indicate that detected or quantifiable hepatitis C virus (HCV) RNA at the end of direct-acting antiviral (DAA) treatment does not preclude sustained virologic response (SVR)12 [1] . Using the Abbott HCV real-time assay (lower limit of quantitation [LLOQ] , 12 IU/mL), the authors reported that among patients treated with sofosbuvir + ledipasvir ± GS-9669 or GS-9451 for 6 or 12 weeks, HCV RNA was detected (<LLOQ or ≥LLOQ) or quantifiable in 29/59 (49%) and 6/59 (10%) patients, respectively, and all but 1 patient achieved an SVR12.
To compare the results by Sidharthan et al with those obtained in other DAA trials, we reanalyzed HCV RNA data from 12 registrational trials of interferon-free, combination DAA treatments [2] [3] [4] to assess the frequency of HCV RNA detection at the end of treatment among patients who achieved SVR12. In these trials, the Roche COBAS TaqMan HCV v2.0 assay (LLOQ = 25 IU/mL) was used, and the regimens were dosed for 8 to 24 weeks in various patient populations. HCV RNA was detected (<LLOQ or ≥LLOQ) at the end of treatment with the Roche v2.0 assay in only 12/3671 (0.3%) patients who achieved SVR12 (Table 1) . Censoring patients who received <4 weeks of treatment or who experienced confirmed virologic breakthrough, a total of 22 patients with detected HCV RNA at the end of treatment were identified from these trials, of whom 12 (55%) achieved SVR12. While these results indicate detected HCV RNA at the end of treatment did not preclude SVR12, they do reflect a higher virologic failure rate than was observed in the general trial populations. Furthermore, for all but 1 of the SVR12-achieving patients, the detected or low quantifiable HCV RNA result was transient, preceded and followed by HCV RNA target-not-detected results, perhaps reflecting nonreproducible sampling of extremely low-level HCV RNA.
The authors' use of the Abbott assay, which has been reported to be more sensitive in detecting low-level HCV RNA during treatment [5] , likely contributed to a higher rate of detected or quantifiable HCV RNA relative to the larger DAA registrational trials. However, the ontreatment HCV RNA results reported by the authors using the Roche COBAS TaqMan HCV v1.0 assay (LLOQ = 43 IU/mL) also appeared higher than expected. For example, among patients treated with sofosbuvir + ledipasvir, 12/ 19 (63%) and 2/19 (11%) had detected or quantifiable HCV RNA at week 4, respectively. In contrast, among patients treated with sofosbuvir + ledipasvir ± ribavirin in the ION-1, -2, and -3 trials, 268/1504 (18%) and 5/1504 (0.3%) patients had detected or quantifiable (≥25 IU/mL, Roche v2.0) HCV RNA at week 4, respectively (Table 1) . Similarly low HCV RNA levels at week 4 were observed in other combination DAA trials. By week 8, HCV RNA was detected in <1% of patients overall. We encourage further analyses of HCV RNA levels using multiple sensitive assays in other short-course DAA combination studies, as these studies will help refine HCV kinetic models and guide future trial design.
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All Reply to Harrington et al TO THE EDITOR-Harrington et al raise 3 important points in a detailed analysis of pooled data from 12 registrational trials of interferon-free, direct-acting antiviral (DAA) therapies [1] .First, the authors point out that hepatitis C virus (HCV) RNA was detected at the end of treatment in only 0.3% (12/3671) of patients who achieved sustained virological response 12 (SVR12) in the larger trials compared to 29% (28/ 96) in our studies [2] . As suggested by 
